Purified anti-human CD326 (EpCAM) Antibody
- 产品名称：
- Purified anti-human CD326 (EpCAM) Antibody
- 产品类别：
- 抗体
- 产品编号：
- 324201
- 产品应用：
- 324201
- Verified Reactivity
- Human
- Antibody Type
- Monoclonal
- Host Species
- Mouse
- Immunogen
- DU.4475 breast carcinoma
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
- Preparation
- The antibody was purified by affinity chromatography.
- Concentration
- 0.5 mg/mL
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C.
- Application
-
FC - Quality tested
ICC?- Verified
IHC - Reported in the literature, not verified in house
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.5 ?g per 106 cells in 100 ?L?volume or 100 ?L?of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
- Application Notes
Additional reported applications (for the revelant formats) include: immunofluorescence,?immunohistochemistry3, and spatial biology (IBEX)4,5.
- Application References
(PubMed link indicates BioLegend citation) -
- Lammers R, et al. 2002. Exp. Hematol. 30:537.
- Schultz LD, et al. 2010. P. Natl. Acad. Sci. USA 107:13022. PubMed
- Human Protein Atlas http://www.proteinatlas.org/ENSG00000119888/antibody (IHC)
- Radtke AJ,?et al. 2020.?Proc Natl Acad Sci USA. 117:33455-33465. (SB)?PubMed
- Radtke AJ,?et al. 2022.?Nat Protoc. 17:378-401. (SB)?PubMed
- Product Citations
-
- de Vargas Roditi L, et al. 2022. Cell Rep Med. 3:100604. PubMed
- Genga RMJ et al. 2019. Cell reports. 27(3):708-718 . PubMed
- Yildizhan Y, et al. 2021. J Extracell Vesicles. e12059:10. PubMed
- Valès S, et al. 2019. EBioMedicine. 49:172. PubMed
- Hutt M, et al. 2018. Oncotarget. 9:11322. PubMed
- Wagner J et al. 2019. Cell. 177(5):1330-1345 . PubMed
- Hinohara K, et al. 2018. Cancer Cell. 34:939. PubMed
- Goh D, et al. 2022. Front Immunol. 13:939989. PubMed
- Morsing M, et al. 2020. Breast Cancer Res. 0.9875. PubMed
- Davies SP, et al. 2019. Cell Rep. 29:1610. PubMed
- Huerta–Nu? ez LFE, et al. 2019. Sci Rep. 9:6419. PubMed
- Salerno–Goncalves R, et al. 2019. PLoS Negl Trop Dis. 13:e0007650. PubMed
- Martin JC, et al. 2020. Cell. 178(6):1493-1508.e20.. PubMed
- Kaneko MK, et al. 2020. Oncol Rep. 44:2517. PubMed
- Batth IS, et al. 2020. BMC Cancer. 20(1):715. PubMed
- Poggi A, et al. 2022. Curr Protoc. 2:e366. PubMed
- Gee MH, et al. 2018. Cell. 172:549. PubMed
- Krishnan V, et al. 2020. Gut. 69:1738. PubMed
- Njock MS, et al. 2022. J Extracell Vesicles. 11:e12228. PubMed
- Shi G, et al. 2022. Methods Mol Biol. 2394:591. PubMed
- Ding L, et al. 2019. Nat Commun. 10:4182. PubMed
- Ruiz–Riquelme A, et al. 2018. Acta Neuropathol Commun. 6:26. PubMed
- Kim J, et al. 2018. J Histochem Cytochem. 66:879. PubMed
- RRID
- AB_756075 (BioLegend Cat. No. 324201) AB_756076 (BioLegend Cat. No. 324202)
- Structure
- Type I transmembrane protein, contains six disulfide bridges, one THYRO domain, approximate molecular weight 40 kD.
- Distribution
-
Highly expressed in bone marrow, colon, lung, and most normal epithelial cells. Also highly expressed on carcinomas of gastrointestinal origin. Expressed during early erythrogenesis.
- Function
- Homotypic calcium-independent cell adhesion. CD326 is believed to be involved in carcinogenesis by its ability to induce genes involved in cellular metabolism and proliferation.
- Modification
- Glycosylated.
- Cell Type
- Embryonic Stem Cells, Epithelial cells
- Biology Area
- Cell Biology, Immunology, Stem Cells
- Molecular Family
- Adhesion Molecules, CD Molecules
- Antigen References
-
1. Strnad J, et al. 1989. Cancer Res. 49:314.
2. Munz M, et al. 2004. Oncogene 23:5748.
3. Rao CG, et al. 2005. Int. J. Oncol. 27:49.
- Gene ID
- 4072 View all products for this Gene ID
- UniProt
- View information about CD326 on UniProt.org
